Lisa Wolf

Lisa Wolf

Auto-generated profile, based on publicly available information

Lisa Wolf

Office of Surveillance and Epidemiology (OSE), Center for Drug Evaluation and Research (CDER), US Food and Drug Administration, Silver Spring, MD, USA

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 June 2025 in Drug Safety
Verified
Journal Article
Open access
PDF file
SJScott Janiczak
Scott Janiczak
STSarah Tanveer
Sarah Tanveer
KTKaren Tom
Karen Tom
RZRongmei Zhang
Rongmei Zhang
YMYong Ma
Yong Ma
MMMonica A. Muñoz
Monica A. Muñoz
Introduction: The Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) receives duplicate reports of adverse events associated with drug and therapeutic biological products. Duplicate reports, defined as multiple reports of the same adverse event(s) related to the administration of the same marketed product(s) to the same individual patient at a particular point in time, may be received in FAERS for many reasons. The presence of duplicate reports can negatively impact public health surveillance efforts by impeding both safety signal identification and signal evaluation. Objectives: To characterize the features and contributing factors associated with duplicate reports in FAERS. Methods: We manually assessed a convenience sample of individual case safety reports (ICSRs) for duplication, resulting in two data sets: one consisting of non-duplicate reports and one with duplicate reports. We then compared key features of these two datasets, including both structured and unstructured data fields. Key comparison features included: report and reporter type, country of report origin, data source for report, and outcome. In addition, we evaluated information similarity of reports for seven data elements (e.g., age, sex, suspect products) within sets of duplicates using both structured and unstructured fields. We used pairwise sentence bidirectional encoder representations from transformers (SBERT) cosine similarity scores to examine free-text narrative similarity. Results: Among the 2297 reports in the sample, 901 (39%) were classified as duplicates, consisting of 237 unique duplicate sets. Compared to non-duplicate reports, duplicates were more likely to be foreign reports (82% versus 37%), reported by healthcare professionals (89% versus 68%), mention other regulatory authority databases (42% versus 11%), describe published case reports (34% versus 11%), or have a serious outcome (97% versus 83%) (p < 0.0001). Within sets of duplicates (n = 237), coded information was frequently different, with only 16% (n = 39) having concordance of all 7 data elements. The narrative was highly similar among most sets of duplicates; we found that the median similarity score for the duplicate pairs was 0.87 compared to 0.48 for non-duplicate pairs. Conclusions: We observed differences in the attributes of and potential contributors to duplicate reports in FAERS that may inform duplicate prevention, detection, and management strategies. However, further studies are needed to better understand the implications of these findings and how potential regulatory changes and technological advances can be leveraged to further address duplicate reporting in adverse event reporting systems.

19 January 2018 in Alimentary Pharmacology & Therapeutics
Verified
Journal Article
Closed access
PDF file
LHL. Harinstein
L. Harinstein
EWE. Wu
E. Wu
ABA. Brinker
A. Brinker

19 December 2018 in Drug Safety
Verified
Journal Article
Closed access
PDF file
LHLisa Harinstein
Lisa Harinstein
Dinesh K. KalraDinesh K. Kalra
Dinesh K. Kalra
CKCindy M. Kortepeter
Cindy M. Kortepeter
MMMonica A. Muñoz
Monica A. Muñoz
EWEileen Wu
Eileen Wu
GPGerald J. Dal Pan
Gerald J. Dal Pan

2 December 2022 in Drug Safety
Verified
Journal Article
Open access
PDF file
IDIda-Lina Diak
Ida-Lina Diak
KSKimberley Swank
Kimberley Swank
KMKate McCartan
Kate McCartan
MBMaya Beganovic
Maya Beganovic
JKJames Kidd
James Kidd
GPGerald Dal Pan
Gerald Dal Pan
Introduction On 4 February, 2020, the Secretary of the Department of Health and Human Services declared a public health emergency related to coronavirus disease 2019 (COVID-19), and on 27 March, 2020 declared circumstances existed to justify the authorization of the emergency use of drug and biological products (hereafter, “drugs”) for COVID-19. At the outset of the pandemic with uncertainty relating to the virus, many drugs were being used to treat or prevent COVID-19, resulting in the US Food and Drug Administration’s (FDA’s) need to initiate heightened surveillance across these drugs. Objective We aimed to describe the FDA’s approach to monitoring the safety of drugs to treat or prevent COVID-19 across multiple data sources and the subsequent actions taken by the FDA to protect public health. Methods The FDA conducted surveillance of adverse event and medication error data using the FDA Adverse Event Reporting System, biomedical literature, FDA-American College of Medical Toxicology COVID-19 Toxicology Investigators Consortium Pharmacovigilance Project Sub-registry, and the American Association of Poison Control Centers National Poison Data System. Results From 4 February, 2020, through 31 January, 2022, we identified 22,944 unique adverse event cases worldwide and 1052 unique medication error cases domestically with drugs to treat or prevent COVID-19. These were from the FDA Adverse Event Reporting System (22,219), biomedical literature (1107), FDA-American College of Medical Toxicology COVID-19 Toxicology Investigator’s Consortium Sub-registry (638), and the National Poison Data System (32), resulting in the detection of several important safety issues. Conclusions Safety surveillance using near real-time data was critical during the COVID-19 pandemic because the FDA monitored an unprecedented number of drugs to treat or prevent COVID-19. Additionally, the pandemic prompted the FDA to accelerate innovation, forging new collaborations and leveraging data sources to conduct safety surveillance to respond to the pandemic.

1 November 2024 in American Journal of Public Health
Verified
Journal Article
Closed access
LWLisa Wolf
Lisa Wolf
MHMichelle Hines
Michelle Hines
OOOliver Ou
Oliver Ou
BWBeverly Wolpert
Beverly Wolpert
NNNichole Nolan
Nichole Nolan
CTCassandra Taylor
Cassandra Taylor
Objective. To characterize adverse event (AE) cases received by the US Food and Drug Administration (FDA) reportedly involving cannabinoid hemp products (CHPs). Methods. We searched the FDA Adverse Event Reporting System and Center for Food Safety and Applied Nutrition Adverse Event Reporting System for cases reported directly to the FDA from 2019–2023 involving CHPs, which are defined as products containing 1 or more of the following: cannabidiol, delta-8 tetrahydrocannabinol, and emerging cannabinoids (i.e., other intoxicating cannabinoids often synthesized from hemp-derived cannabidiol). We abstracted and summarized information on reporting trends, consumer demographics, reporter information, product information, and AEs. Results. We identified 610 AE cases reportedly involving CHPs containing 1 or more of the following: delta-8 tetrahydrocannabinol (n=355), cannabidiol (n=253), and emerging cannabinoids (n=36). Multiple trends and safety issues were identified, including an annual increase in the number of cases involving intoxicating cannabinoids since 2021, potential quality issues, and the occurrence of fatalities and pediatric exposures. Conclusions. Our findings emphasize the importance of monitoring AE cases received by the FDA involving CHPs as part of a comprehensive surveillance strategy to identify trends and safety issues with these products. ( Am J Public Health. 2024;114(S8):S664–S672. https://doi.org/10.2105/AJPH.2024.307712 )

25 July 2025 in Drug Safety
Verified
Journal Article
Open access
SJScott Janiczak
Scott Janiczak
STSarah Tanveer
Sarah Tanveer
KTKaren Tom
Karen Tom
RZRongmei Zhang
Rongmei Zhang
YMYong Ma
Yong Ma
MMMonica A. Muñoz
Monica A. Muñoz